Welcome to LookChem.com Sign In|Join Free

CAS

  • or
2-Bromo-1-(3,4-difluorophenyl)ethan-1-one is an organic compound characterized by the presence of a bromine atom at the 2nd carbon, a 3,4-difluorophenyl group attached to the 1st carbon, and a carbonyl group (C=O) at the 1st position. 2-Bromo-1-(3,4-difluorophenyl)ethan-1-one is known for its potential applications in the pharmaceutical and chemical industries due to its unique structural features.

40706-98-7 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 40706-98-7 Structure
  • Basic information

    1. Product Name: 2-Bromo-1-(3,4-difluorophenyl)ethan-1-one
    2. Synonyms: 2-BROMO-3',4'-DIFLUOROACETOPHENONE;2-BROMO-1-(3,4-DIFLUOROPHENYL)ETHAN-1-ONE;3',4'-DIFLUOROPHENACYL BROMIDE;3,4-DIFLUOROPHENACYL BROMIDE;BUTTPARK 35\01-53;3,4-Difluorophenacyl bromide 98%;3,4-Difluorophenacylbromide98%;3,4-difluorophenacyl bromide ,2-bromo-1-(3,4-dichlorophenyl)ethanone
    3. CAS NO:40706-98-7
    4. Molecular Formula: C8H5BrF2O
    5. Molecular Weight: 235.03
    6. EINECS: N/A
    7. Product Categories: Acetophenone series
    8. Mol File: 40706-98-7.mol
  • Chemical Properties

    1. Melting Point: 28 °C
    2. Boiling Point: 261 °C at 760 mmHg
    3. Flash Point: 110 °C
    4. Appearance: /
    5. Density: 1.648 g/cm3
    6. Vapor Pressure: 0.0119mmHg at 25°C
    7. Refractive Index: 1.529
    8. Storage Temp.: N/A
    9. Solubility: N/A
    10. CAS DataBase Reference: 2-Bromo-1-(3,4-difluorophenyl)ethan-1-one(CAS DataBase Reference)
    11. NIST Chemistry Reference: 2-Bromo-1-(3,4-difluorophenyl)ethan-1-one(40706-98-7)
    12. EPA Substance Registry System: 2-Bromo-1-(3,4-difluorophenyl)ethan-1-one(40706-98-7)
  • Safety Data

    1. Hazard Codes: C,F
    2. Statements: 34-36/37/38
    3. Safety Statements: 26-36/37/39-45
    4. RIDADR: 3261
    5. WGK Germany:
    6. RTECS:
    7. HazardClass: CORROSIVE
    8. PackingGroup: N/A
    9. Hazardous Substances Data: 40706-98-7(Hazardous Substances Data)

40706-98-7 Usage

Uses

Used in Pharmaceutical Industry:
2-Bromo-1-(3,4-difluorophenyl)ethan-1-one is used as a reagent for the preparation of new classes of anti-trypanosomal agents. Specifically, it is utilized in the synthesis of imidazopyridine-based compounds, which have shown potential as effective treatments against trypanosomal infections, such as those caused by Trypanosoma brucei, the parasite responsible for African sleeping sickness.
The application of 2-Bromo-1-(3,4-difluorophenyl)ethan-1-one in the pharmaceutical industry is primarily due to its ability to contribute to the development of novel therapeutic agents with improved efficacy and selectivity against trypanosomal diseases. 2-Bromo-1-(3,4-difluorophenyl)ethan-1-one serves as a key building block in the synthesis of these potential drugs, enabling the creation of diverse chemical structures with enhanced biological activities.

Check Digit Verification of cas no

The CAS Registry Mumber 40706-98-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 4,0,7,0 and 6 respectively; the second part has 2 digits, 9 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 40706-98:
(7*4)+(6*0)+(5*7)+(4*0)+(3*6)+(2*9)+(1*8)=107
107 % 10 = 7
So 40706-98-7 is a valid CAS Registry Number.
InChI:InChI=1/C8H5BrF2O/c9-4-8(12)5-1-2-6(10)7(11)3-5/h1-3H,4H2

40706-98-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 20, 2017

Revision Date: Aug 20, 2017

1.Identification

1.1 GHS Product identifier

Product name 2-Bromo-1-(3,4-difluorophenyl)ethanone

1.2 Other means of identification

Product number -
Other names 2-Bromo-3',4'-difluoroacetophenone

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:40706-98-7 SDS

40706-98-7Upstream product

40706-98-7Relevant articles and documents

Polysubstituted Ligand Framework for Color Tuning Phosphorescent Iridium(III) Complexes

Beames, Joseph M.,Coles, Simon J.,Elgar, Christopher E.,Fitzgerald, Sophie A.,Horton, Peter N.,Otaif, Haleema Y.,Pope, Simon J. A.,Sawicka, Natalia

, p. 15467 - 15484 (2021/10/20)

A series of ligands have been synthesized based upon a polysubstituted 2-phenylquinoxaline core structure. These ligands introduce different combinations of fluorine and methyl substituents on both the phenyl and quinoxaline constituent rings. The resultant investigation of these species as cyclometalating agents for Ir(III) gave cationic complexes of the form [Ir(C^N)2(bipy)]PF6 (where C^N = cyclometalating ligand; bipy = 2,2′-bipyridine). X-ray crystallographic studies were conducted on four complexes and each revealed the expected distorted octahedral geometry based upon a cis-C,C and trans-N,N ligand arrangement at Ir(III). Supporting computational studies predict that each of the complexes share the same general descriptions for the frontier orbitals. TD-DFT calculations suggest MLCT contributions to the lowest energy absorption and a likely MLCT/ILCT/LLCT nature to the emitting state. Experimentally, the complexes display tunable luminescence across the yellow-orange-red part of the visible spectrum (λem = 579-655 nm).

Novel BuChE-IDO1 inhibitors from sertaconazole: Virtual screening, chemical optimization and molecular modeling studies

Zhou, You,Lu, Xin,Du, Chenxi,Liu, Yijun,Wang, Yifan,Hong, Kwon Ho,Chen, Yao,Sun, Haopeng

, (2021/01/07)

In our effort towards the identification of novel BuChE-IDO1 dual-targeted inhibitor for the treatment of Alzheimer's disease (AD), sertaconazole was identified through a combination of structure-based virtual screening followed by MM-GBSA rescoring. Preliminary chemical optimization was performed to develop more potent and selective sertaconazole analogues. In consideration of the selectivity and the inhibitory activity against target proteins, compounds 5c and 5d were selected for the next study. Further modification of compound 5c led to the generation of compound 10g with notably improved selectivity towards BuChE versus AChE. The present study provided us with a good starting point to further design potent and selective BuChE-IDO1 inhibitors, which may benefit the treatment of late stage AD.

BuChE-IDO1 inhibitor as well as preparation method and application thereof

-

Paragraph 0070-0072; 0090-0091, (2021/04/26)

The invention relates to the field of medicines, and particularly discloses a BuChE-IDO1 inhibitor as well as a preparation method and application thereof. The 7-chlorine-3-substituted benzothiophene part of sertaconazole is chemically modified, the influence of the 7-chlorine-3-substituted benzothiophene part of sertaconazole on the in-vitro inhibitory activity of AChE, BuChE and IDO1 is explored, the target compound is further optimized, and the technical problems that an existing BuChE-IDO1 inhibitor is poor in pertinence and safety are solved. What is explored is that an appropriate substituent group introduced to a 2-benzothiazole ring can form additional interaction with surrounding amino acids and heme iron, so that the binding affinity of the analogue with BuChE and IDO1 is increased, and a new idea is broadened for more efficient and targeted treatment of advanced AD diseases.

4-AMINOBUT-2-ENAMIDE DERIVATIVES AND SALTS THEREOF

-

Paragraph 0412, (2021/05/07)

The present invention provides an antitumor agent comprising a compound or a pharmaceutically acceptable salt thereof that covalently binds to GTP-bound KRASG12C as an active ingredient.

Thiazole ring-containing amide compounds as well as preparation method and application thereof

-

Paragraph 0044; 0051; 0058; 0061; 0122; 0127; 0206; 0211, (2021/06/23)

The invention discloses thiazole ring-containing amide compounds as well as a preparation method and application thereof, and belongs to the field of chemical technologies and pesticides. According to the present invention, p-phenylenediamine is adopted as a raw material to synthesize a series of the thiazole ring-containing amide compounds, and the synthesized thiazole ring-containing amide compounds have good inhibition effects on Xanthomonas oryzae pv.Oryza (Xoo), Xanthomonas oryzae pv.Oryzcola (Xoc) and Xanthomonas axonophora pv.Citri (Xac) in agricultural diseases and insect pests, and can be used for preparing the anti-plant bacterium agent.

Microwave-assisted synthesis and luminescent activity of imidazo[1,2-a]pyridine derivatives

Rodríguez, Juan C.,Maldonado, Rony A.,Ramírez-García, Gonzalo,Díaz Cervantes, Erik,de la Cruz, Fabiola N.

, p. 2279 - 2287 (2020/03/16)

In this work, a series of phenacyl bromide derivatives was synthesized and employed as key intermediate for the synthesis of substituted imidazo[1,2-a]pyridines. First, phenacyl bromide molecules were obtained from the bromination reaction of acetophenones assisted by microwave irradiation, obtaining the products 4a-v in a 15 minutes reaction with yields in the range of 50% to 99%. Subsequently, the conjugation of these molecules with 2-aminopyridine conduced to the production of imidazo[1,2-a]pyridine derivatives (7a-v) in a 60-second reaction with yields of 24% to 99%. Improved yields were determined with respect to those obtained with more tedious methodologies like thermally and mechanically assisted routes. Intense luminescence emissions in the purple and blue regions of the electromagnetic spectra were observed under UV excitation according to the nature of the substituents. This environmentally friendly methodology is expected to constitute an important class of organic compounds for the development of biomarkers, photochemical sensors, and medicinal applications.

Usnic Acid Enaminone-Coupled 1,2,3-Triazoles as Antibacterial and Antitubercular Agents

Bangalore, Pavan K.,Vagolu, Siva K.,Bollikanda, Rakesh K.,Veeragoni, Dileep K.,Choudante, Pallavi C.,Misra, Sunil,Sriram, Dharmarajan,Sridhar, Balasubramanian,Kantevari, Srinivas

supporting information, p. 26 - 35 (2020/01/03)

(+)-Usnic acid, a product of secondary metabolism in lichens, has displayed a broad range of biological properties such as antitumor, antimicrobial, antiviral, anti-inflammatory, and insecticidal activities. Interested by these pharmacological activities and to tap into its potential, we herein present the synthesis and biological evaluation of new usnic acid enaminone-conjugated 1,2,3-triazoles 10-44 as antimycobacterial agents. (+)-Usnic acid was condensed with propargyl amine to give usnic acid enaminone 8 with a terminal ethynyl moiety. It was further reacted with various azides A1-A35 under copper catalysis to give triazoles 10-44 in good yields. Among the synthesized compounds, saccharin derivative 36 proved to be the most active analogue, inhibiting Mycobacterium tuberculosis (Mtb) at an MIC value of 2.5 μM. Analogues 16 and 27, with 3,4-difluorophenacyl and 2-acylnaphthalene units, respectively, inhibited Mtb at MIC values of 5.4 and 5.3 μM, respectively. Among the tested Gram-positive and Gram-negative bacteria, the new derivatives were active on Bacillus subtilis, with compounds 18 [3-(trifluoromethyl)phenacyl] and 29 (N-acylmorpholinyl) showing inhibitory concentrations of 41 and 90.7 μM, respectively, while they were inactive on the other tested bacterial strains. Overall, the study presented here is useful for converting natural (+)-usnic acid into antitubercular and antibacterial agents via incorporation of enaminone and 1,2,3-triazole functionalities.

Synthesis and Antibacterial Evaluation of N-phenylacetamide Derivatives Containing 4-Arylthiazole Moieties

Jin, Linhong,Lu, Hui,Wang, Lei,Zhou, Xia

, (2020/04/23)

A series of new N-phenylacetamide derivatives containing 4-arylthiazole moieties was designed and synthesized by introducing the thiazole moiety into the amide scaffold. The structures of the target compounds were confirmed by 1H-NMR, 13C-NMR and HRMS. Their in vitro antibacterial activities were evaluated against three kinds of bacteria-Xanthomonas oryzae pv. Oryzae (Xoo), Xanthomonas axonopodis pv. Citri (Xac) and X.oryzae pv. oryzicola (Xoc)-showing promising results. The minimum 50% effective concentration (EC50) value of N-(4-((4-(4-fluoro-phenyl)thiazol-2-yl)amino)phenyl)acetamide (A1) is 156.7 μM, which is superior to bismerthiazol (230.5 μM) and thiodiazole copper (545.2 μM). A scanning electron microscopy (SEM) investigation has confirmed that compound A1 could cause cell membrane rupture of Xoo. In addition, the nematicidal activity of the compounds against Meloidogyne incognita (M. incognita) was also tested, and compound A23 displayed excellent nematicidal activity, with mortality of 100% and 53.2% at 500 μg/mL and 100 μg/mL after 24 h of treatment, respectively. The preliminary structure-activity relationship (SAR) studies of these compounds are also briefly described. These results demonstrated that phenylacetamide derivatives may be considered as potential leads in the design of antibacterial agents.

Development of triazolothiadiazine derivatives as highly potent tubulin polymerization inhibitors: Structure-activity relationship, in vitro and in vivo study

Ma, Weifeng,Chen, Peng,Huo, Xiansen,Ma, Yufeng,Li, Yanhong,Diao, Pengcheng,Yang, Fang,Zheng, Shengquan,Hu, Mengjin,You, Wenwei,Zhao, Peiliang

, (2020/10/08)

Based on our prior work, we reported the design, synthesis, and biological evaluation of fifty-two new triazolothiadiazine-based analogues of CA-4 and their preliminary structure-activity relationship. Among synthesized compounds, Iab was found to be the most potent derivative possessing IC50 values ranging from single-to double-digit nanomolar in vitro, and also exhibited excellent selectivity over the normal human embryonic kidney HEK-293 cells (IC50 > 100 μM). Further mechanistic studies revealed that Iab significantly blocked tubulin polymerization and disrupted the intracellular microtubule network of A549 cells. Moreover, Iab induced G2/M cell cycle arrest by regulation of p-cdc2 and cyclin B1 expressions, and caused cell apoptosis through up-regulating cleaved PARP and cleaved caspase-3 expressions, and down-regulating of Bcl-2. Importantly, in vivo, Iab effectively suppressed tumor growth of A549 lung cancers in a xenograft mouse model without obvious signs of toxicity, confirming its potential as a promising candidate for cancer treatment.

Discovery of novel potent GPR40 agonists containing imidazo[1,2-a]pyridine core as antidiabetic agents

Ye, Zhiwen,Liu, Chunxia,Zou, Feng,Cai, Yan,Chen, Bin,Zou, Yuxing,Mo, Jiaxian,Han, Ting,Huang, Wenlong,Qiu, Qianqian,Qian, Hai

, (2020/06/19)

Free fatty acid receptor 1 (FFA1 or GPR40) has been studied for many years as a target for the treatment of type 2 diabetes mellitus. In order to increase potency and reduce hepatotoxicity, a series of novel compounds containing imidazo[1,2-a]pyridine sca

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 40706-98-7